For example, Yildirim et al. conducted [70] a multicenter retrospective study on 46 male patients with HR+ and HER2-breast cancer, treated with palbociclib or ribociclib, proving that these therapeutic agents are effective and safe options in these kinds of patients, and supporting the use of CDK 4/6 inhibitor-based combinations as standard treatment in males also. The gene discussed is ERBB2; the disease is breast carcinoma.